USC.edu
Are You a Patient?

Jacob Stephen Thomas, MD

Assistant Professor of Clinical Medicine

Service Chief of LAC+USC Oncology

Image of Jacob Stephen Thomas, MD
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Publications

  • Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. Br J Cancer. 2026 Jun; 134(11):1568-1579.. View in PubMed
  • CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study. J Immunother Cancer. 2026 Mar 27; 14(3).. View in PubMed
  • Outcomes of Patients With Solid Tumor Treated on Phase I Clinical Trials Within a Comprehensive Cancer Center’s Private and Safety-Net Hospitals. JCO Oncol Pract. 2025 Dec 03.. View in PubMed
  • Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study. EBioMedicine. 2025 Nov; 121:105980.. View in PubMed
  • Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review. Drugs Real World Outcomes. 2025 Jun; 12(2):295-300.. View in PubMed
  • Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Res Commun. 2025 05 01; 5(5):767-773.. View in PubMed
  • Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. Cancer Res Commun. 2025 02 01; 5(2):277-286.. View in PubMed
  • Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations. Discov Oncol. 2024 Nov 21; 15(1):689.. View in PubMed
  • Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020. Cancers (Basel). 2024 Mar 08; 16(6).. View in PubMed
  • Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report. Oral Oncol. 2023 12; 147:106597.. View in PubMed

Similar People